Spectranetics
Spectranetics is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Spectranetics.
Spectranetics is a company.
Key people at Spectranetics.
Key people at Spectranetics.
Spectranetics Corporation, founded in 1984 and headquartered in Colorado Springs, Colorado, developed, manufactured, and distributed single-use medical devices for minimally invasive cardiovascular procedures using proprietary excimer laser technology.[1][2][3] Its products treated arterial blockages in the legs and heart, managed thrombus, and removed pacemaker and defibrillator leads, serving cardiologists, vascular specialists, and patients with peripheral arterial disease (PAD), coronary disease, and lead complications through laser catheters, aspiration tools, scoring balloons, and drug-coated balloons like the Stellarex platform.[2][3][4] The company solved challenges in crossing and ablating tough lesions—such as calcified plaque and thrombus—without significant thermal damage to surrounding tissue, enabling better blood flow restoration; it achieved revenue growth up to 47% in peak years and expanded globally to over 65 countries before its acquisition by Philips in 2017, after which it integrated into Philips' Image-Guided Therapy group.[2][3][4]
Spectranetics was founded in 1984 by Robert Golobic, PhD, and Johan Sverdrup, who envisioned using excimer laser technology to treat coronary lesions and restore blood flow, starting with limited funding and persistence that led to FDA approval for peripheral and coronary arterial disease treatments in 1993.[1][3] The company went public in 1992, raising funds by selling 2.5 million shares at $13.50 each, with the stock quickly rising above $20.[5] Early challenges included the deaths of both founders, a class-action lawsuit, and a federal investigation, alongside slow revenue growth despite the technology's promise; a turnaround began in 2011 under CEO Scott Drake and COO Shar Matin, who implemented the High Performance Management System (HPMS) to focus on "Vital Few" priorities like peripheral expansion and lead management, driving execution and culture.[1]
Spectranetics rode the wave of advancing minimally invasive cardiovascular interventions, particularly atherectomy and lead management, outpacing market growth through laser innovation amid rising PAD prevalence and aging populations.[3] Its timing capitalized on FDA approvals in the 1990s and 2010s product expansions, addressing unmet needs in complex lesions where traditional tools failed, while influencing medtech by proving excimer lasers' efficacy in over 65 countries and setting benchmarks for laser-based therapies.[1][2][4] The 2017 Philips acquisition amplified its impact, integrating into a leader in image-guided therapy and accelerating adoption of tools like Stellarex amid trends in drug-coated devices and hybrid procedures.[4]
Post-2017 acquisition, Spectranetics operates as a Philips subsidiary, with its laser and VI technologies likely evolving within Philips' ecosystem of diagnostic imaging and informatics to enhance precision therapies.[2][4] Trends like AI-guided interventions, expanding PAD markets, and lead extraction demands from rising implant volumes will shape its trajectory, potentially driving further innovations in ablation and drug delivery.[3][4] Its legacy of turnaround and tech leadership positions Philips to influence cardiovascular care, tying back to the founders' vision of laser-enabled blood flow restoration now scaled globally.
